Gitlab Inc vs Humana Inc — how do they compare? Gitlab Inc trades at $55.07 (market cap $8.92B), while Humana Inc trades at $436 (market cap $46.49B). The key difference: Humana Inc is far larger — about 5.2× Gitlab Inc's market cap, and Humana Inc pays a 0.91% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Humana Inc for 51 Days on average.
| GTLB | HUM | |
|---|---|---|
Market Cap | $8.92B | $46.49B |
Volume | 4,716,893 | 2,567,704 |
Sector | Technology | Health |
52-Week High | $53.56 | $409.85 |
52-Week Low | $19.42 | $163.67 |
Typical Hold Time | 62 Days | 51 Days |
Enterprise Value | $7.66B | $53.84B |
Dividend Yield | — | 0.91% |
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $55.09, up 5.96% today and near its 52-week high, with strong technical momentum. The company shows impressive revenue growth, reaching $759M in 2025, though it remains unprofitable with a net margin of -4.99%. Recent Q2 2026 earnings beat expectations with EPS of $0.24 versus $0.18 expected, driven by AI product traction and sales momentum. Analyst sentiment is mixed with a Hold consensus but positive news flow highlights AI-driven demand and raised guidance.
Outlook: GTLB benefits from AI integration in DevSecOps and strong execution, but high valuation (P/E 521) and persistent losses pose risks. Investment case hinges on sustained revenue growth and path to profitability. Key risks include competitive pressure and reliance on AI adoption trends.
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →